HC Wainwright Has Pessimistic View of AXSM FY2025 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, November 4th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($3.49) for the year, down from their prior estimate of ($3.19). HC Wainwright currently has a “Buy” rating and a $185.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at $0.46 EPS, Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.66 EPS and FY2026 earnings at $2.84 EPS.

Other equities research analysts have also recently issued reports about the stock. Mizuho upped their target price on shares of Axsome Therapeutics from $200.00 to $202.00 and gave the company an “outperform” rating in a report on Thursday. Guggenheim boosted their price target on Axsome Therapeutics from $200.00 to $205.00 and gave the company a “buy” rating in a research report on Tuesday. B. Riley started coverage on Axsome Therapeutics in a research note on Wednesday, October 1st. They set a “buy” rating and a $179.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Finally, Bank of America lifted their target price on Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Axsome Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $179.88.

Axsome Therapeutics Trading Down 0.9%

NASDAQ:AXSM opened at $138.15 on Thursday. The company has a market capitalization of $6.89 billion, a PE ratio of -27.25 and a beta of 0.50. Axsome Therapeutics has a 52-week low of $75.56 and a 52-week high of $141.36. The stock’s 50 day moving average price is $124.71 and its 200 day moving average price is $113.61. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The business had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm’s revenue for the quarter was up 63.2% compared to the same quarter last year.

Insider Buying and Selling

In related news, CEO Herriot Tabuteau sold 21,775 shares of the business’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $134.49, for a total value of $2,928,519.75. Following the sale, the chief executive officer directly owned 7,229 shares in the company, valued at $972,228.21. The trade was a 75.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total transaction of $1,159,600.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 407,271 shares of company stock worth $50,640,415. Insiders own 22.30% of the company’s stock.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AXSM. Norges Bank acquired a new stake in Axsome Therapeutics in the second quarter worth about $48,889,000. Nuveen LLC bought a new stake in shares of Axsome Therapeutics during the 1st quarter worth about $48,185,000. Adage Capital Partners GP L.L.C. lifted its stake in shares of Axsome Therapeutics by 831.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after acquiring an additional 399,000 shares during the period. Hood River Capital Management LLC acquired a new stake in shares of Axsome Therapeutics in the 2nd quarter worth approximately $38,740,000. Finally, 1832 Asset Management L.P. bought a new position in shares of Axsome Therapeutics in the first quarter valued at approximately $42,360,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.